≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Relapsing polychondritis

DOID EFO Endpoint Browser PheWeb

M13_RELAPSPOLYCHONDR

relapsing polychondritis: Relapsing polychondritis (RP) is a rare, clinically heterogeneous, multisystemic inflammatory disease characterized by inflammation of the cartilage and proteoglycan rich structures leading to cartilage damage with joint, ocular and cardiovascular involvement.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — M94.1
  • Cause of death: ICD-10 — M94.1

2 out of 7 registries used, show all original rules.

88

4. Check minimum number of events

None

88

5. Include endpoints

None

88

6. Filter based on genotype QC (FinnGen only)

84

Control definitions (FinnGen only)

Control exclude
M13_OTHERBONE

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
M94
Name in latin
Polychondritis recidiva

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 349 227 121
Only index persons 333 217 116
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.00
Only index persons 0.01 0.01 0.00
Median age at first event (years)
Whole population 52.03 50.64 54.42
Only index persons 51.38 50.03 53.90

-FinnGen-

Key figures

All Female Male
Number of individuals 84 61 23
Unadjusted period prevalence (%) 0.02 0.02 0.01
Median age at first event (years) 51.46 49.84 55.76

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
88
Matched controls
880
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M94.1
ICD-10 Finland
Relapsing polychondritis
+∞
126.7
88
*
L04AX03
ATC
methotrexate; systemic
22.3
50.6
53
56
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
15.3
38.2
48
64
H02AB06
ATC
prednisolone; systemic
8.2
16.3
72
311
H61.0
ICD-10 Finland
Perichondritis of external ear
+∞
12.8
12
*
P01BA02
ATC
hydroxychloroquine; oral
6.4
11.8
23
46
L04AX01
ATC
azathioprine; systemic
18.8
11.4
17
11
A46
ICD-10 Finland
Erysipelas
5.6
11.2
26
61
L01BA01
ATC
methotrexate; systemic
17.2
11.0
17
12
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
6.5
10.2
19
36
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.4
10.0
60
289
H02AB07
ATC
prednisone; oral
5.3
9.9
24
58
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.1
9.6
42
161
R03BA05
ATC
fluticasone; inhalant
4.0
7.8
29
97
L30.9
ICD-10 Finland
Dermatitis, unspecified
3.8
7.7
31
110
H62.0*A46
ICD-10 Finland
Otitis externa in erysipelas
33.0
7.3
9
*
J01DB01
ATC
cefalexin; oral
10.0
7.2
85
651
H60.1
ICD-10 Finland
Cellulitis of external ear
24.8
6.8
9
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.1
6.4
45
221
J01FA06
ATC
roxithromycin; oral
3.1
6.4
51
269
M94.9
ICD-10 Finland
Disorder of cartilage, unspecified
+∞
6.3
6
*

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
prednisolone; oral, parenteral
H02AB06 [21602734]
1.2e+00
2.7e+00
3.5e+00
1.0e+50
3.6e+00
3.0e+00
2.2e+00
cases:23.86%
controls:8.98%
cases:34.09%
controls:3.52%
cases:19.32%
controls:0.68%
cases:9.09%
controls:0.00%
cases:26.14%
controls:0.91%
cases:45.24%
controls:3.92%
cases:51.32%
controls:10.75%
21
79
67
801
30
31
58
849
17
6
71
874
8
0
80
880
23
8
65
871
38
33
46
809
39
80
37
664
prednisolone
A07EA01 [21600653]
1.2e+00
2.7e+00
3.5e+00
1.0e+50
3.6e+00
3.0e+00
2.2e+00
cases:23.86%
controls:8.98%
cases:34.09%
controls:3.52%
cases:19.32%
controls:0.68%
cases:9.09%
controls:0.00%
cases:26.14%
controls:0.91%
cases:45.24%
controls:3.92%
cases:51.32%
controls:10.75%
21
79
67
801
30
31
58
849
17
6
71
874
8
0
80
880
23
8
65
871
38
33
46
809
39
80
37
664
methotrexate
L01BA01 [21601423]
—
2.2e+00
—
1.0e+50
—
4.9e+00
4.2e+00
—
—
cases:7.95%
controls:0.91%
—
—
cases:7.95%
controls:0.00%
—
—
cases:44.05%
controls:0.59%
cases:47.37%
controls:1.34%
—
7
8
81
872
—
7
0
81
880
—
37
5
47
837
36
10
40
734
methotrexate; oral, parenteral
L04AX03 [21603929]
—
2.2e+00
—
1.0e+50
—
4.9e+00
4.2e+00
—
—
cases:7.95%
controls:0.91%
—
—
cases:7.95%
controls:0.00%
—
—
cases:44.05%
controls:0.59%
cases:47.37%
controls:1.34%
—
7
8
81
872
—
7
0
81
880
—
37
5
47
837
36
10
40
734
Otolaryngology
4 [38004449]
1.2e+00
2.5e+00
3.0e+00
1.0e+50
—
2.4e+00
1.3e+00
cases:27.27%
controls:10.00%
cases:34.09%
controls:4.20%
cases:12.50%
controls:0.68%
cases:26.14%
controls:0.00%
—
—
cases:26.19%
controls:2.97%
cases:30.26%
controls:10.22%
24
88
64
792
30
37
58
843
11
6
77
874
23
0
65
880
—
22
25
62
817
23
76
53
668
Monocytes [#/volume] in Blood
26484-6 [3001604]
7.9e-01
1.4e+00
2.6e+00
—
2.9e+00
2.0e+00
1.4e+00
cases:19.32%
controls:9.77%
cases:23.86%
controls:6.93%
cases:19.32%
controls:1.70%
—
—
cases:11.36%
controls:0.68%
cases:32.14%
controls:5.82%
cases:39.47%
controls:14.38%
17
86
71
794
21
61
67
819
17
15
71
865
—
10
6
78
873
27
49
57
793
30
107
46
637
Basophils [#/volume] in Blood
26444-0 [3006315]
8.1e-01
1.4e+00
2.6e+00
—
2.9e+00
2.0e+00
1.4e+00
cases:19.32%
controls:9.66%
cases:23.86%
controls:7.05%
cases:19.32%
controls:1.70%
—
—
cases:11.36%
controls:0.68%
cases:32.14%
controls:5.82%
cases:39.47%
controls:14.38%
17
85
71
795
21
62
67
818
17
15
71
865
—
10
6
78
873
27
49
57
793
30
107
46
637
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
6.9e-01
1.4e+00
2.6e+00
—
2.8e+00
2.0e+00
1.3e+00
cases:19.32%
controls:10.68%
cases:23.86%
controls:7.05%
cases:19.32%
controls:1.70%
—
—
cases:11.36%
controls:0.80%
cases:32.14%
controls:6.06%
cases:39.47%
controls:14.92%
17
94
71
786
21
62
67
818
17
15
71
865
—
10
7
78
872
27
51
57
791
30
111
46
633
Eosinophils [#/volume] in Blood
26449-9 [3013115]
7.8e-01
1.4e+00
2.6e+00
—
2.8e+00
2.0e+00
1.3e+00
cases:19.32%
controls:9.89%
cases:23.86%
controls:7.27%
cases:19.32%
controls:1.70%
—
—
cases:11.36%
controls:0.80%
cases:32.14%
controls:5.94%
cases:39.47%
controls:14.78%
17
87
71
793
21
64
67
816
17
15
71
865
—
10
7
78
872
27
50
57
792
30
110
46
634
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
6.4e-01
1.4e+00
2.5e+00
—
2.8e+00
2.0e+00
1.3e+00
cases:17.05%
controls:9.77%
cases:21.59%
controls:6.59%
cases:18.18%
controls:1.70%
—
—
cases:11.36%
controls:0.80%
cases:29.76%
controls:5.23%
cases:36.84%
controls:13.17%
15
86
73
794
19
58
69
822
16
15
72
865
—
10
7
78
872
25
44
59
798
28
98
48
646
Monocytes/Leukocytes in Blood
26485-3 [3019069]
7.6e-01
1.4e+00
2.5e+00
—
2.6e+00
2.0e+00
1.4e+00
cases:18.18%
controls:9.43%
cases:22.73%
controls:6.82%
cases:18.18%
controls:1.70%
—
—
cases:10.23%
controls:0.80%
cases:29.76%
controls:5.46%
cases:36.84%
controls:12.90%
16
83
72
797
20
60
68
820
16
15
72
865
—
9
7
79
872
25
46
59
796
28
96
48
648
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
7.4e-01
1.4e+00
2.5e+00
—
2.6e+00
2.0e+00
1.4e+00
cases:18.18%
controls:9.55%
cases:22.73%
controls:6.82%
cases:18.18%
controls:1.70%
—
—
cases:10.23%
controls:0.80%
cases:29.76%
controls:5.46%
cases:36.84%
controls:12.90%
16
84
72
796
20
60
68
820
16
15
72
865
—
9
7
79
872
25
46
59
796
28
96
48
648
Basophils/Leukocytes in Blood
30180-4 [3022096]
7.4e-01
1.4e+00
2.5e+00
—
2.6e+00
2.0e+00
1.4e+00
cases:18.18%
controls:9.55%
cases:22.73%
controls:6.82%
cases:18.18%
controls:1.70%
—
—
cases:10.23%
controls:0.80%
cases:29.76%
controls:5.46%
cases:36.84%
controls:13.04%
16
84
72
796
20
60
68
820
16
15
72
865
—
9
7
79
872
25
46
59
796
28
97
48
647
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
6.7e-01
1.4e+00
2.5e+00
—
2.6e+00
2.0e+00
1.3e+00
cases:18.18%
controls:10.23%
cases:22.73%
controls:6.70%
cases:18.18%
controls:1.70%
—
—
cases:10.23%
controls:0.80%
cases:29.76%
controls:5.46%
cases:36.84%
controls:13.44%
16
90
72
790
20
59
68
821
16
15
72
865
—
9
7
79
872
25
46
59
796
28
100
48
644
Rheumatology
66 [38004491]
1.1e+00
2.1e+00
—
—
—
4.2e+00
3.6e+00
cases:9.09%
controls:3.18%
cases:14.77%
controls:2.16%
—
—
—
—
—
—
cases:53.57%
controls:1.78%
cases:59.21%
controls:3.90%
8
28
80
852
13
19
75
861
—
—
—
45
15
39
827
45
29
31
715
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4.2e-01
1.3e+00
2.9e+00
—
2.5e+00
1.8e+00
1.2e+00
cases:23.86%
controls:17.05%
cases:26.14%
controls:8.75%
cases:17.05%
controls:1.14%
—
—
cases:10.23%
controls:0.91%
cases:36.90%
controls:8.43%
cases:46.05%
controls:20.97%
21
150
67
730
23
77
65
803
15
10
73
870
—
9
8
79
871
31
71
53
771
35
156
41
588
cefalexin; oral
J01DB01 [21602870]
9.4e-01
1.5e+00
2.9e+00
—
2.2e+00
1.5e+00
6.6e-01
cases:52.27%
controls:30.00%
cases:31.82%
controls:9.32%
cases:11.36%
controls:0.68%
—
—
cases:7.95%
controls:0.91%
cases:28.57%
controls:8.55%
cases:43.42%
controls:28.36%
46
264
42
616
28
82
60
798
10
6
78
874
—
7
8
81
871
24
72
60
770
33
211
43
533
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
8.1e-01
1.2e+00
2.3e+00
—
2.1e+00
2.0e+00
1.3e+00
cases:20.45%
controls:10.23%
cases:22.73%
controls:7.95%
cases:18.18%
controls:2.16%
—
—
cases:12.50%
controls:1.71%
cases:32.14%
controls:6.18%
cases:39.47%
controls:15.46%
18
90
70
790
20
70
68
810
16
19
72
861
—
11
15
77
864
27
52
57
790
30
115
46
629
Differential panel, method unspecified - Blood
69738-3 [42870588]
2.4e-01
9.6e-01
2.4e+00
1.0e+50
2.5e+00
1.9e+00
1.6e+00
cases:7.95%
controls:6.36%
cases:11.36%
controls:4.66%
cases:11.36%
controls:1.14%
cases:5.68%
controls:0.00%
cases:7.95%
controls:0.68%
cases:23.81%
controls:4.63%
cases:32.89%
controls:9.01%
7
56
81
824
10
41
78
839
10
10
78
870
5
0
83
880
7
6
81
873
20
39
64
803
25
67
51
677
hydroxychloroquine; oral
P01BA02 [21604889]
2.0e+00
2.5e+00
—
—
—
2.7e+00
2.8e+00
cases:6.82%
controls:1.02%
cases:9.09%
controls:0.80%
—
—
—
—
—
—
cases:10.71%
controls:0.83%
cases:17.11%
controls:1.21%
6
9
82
871
8
7
80
873
—
—
—
9
7
75
835
13
9
63
735
prednisone
A07EA03 [21600655]
2.2e+00
2.9e+00
—
—
—
2.4e+00
2.3e+00
cases:5.68%
controls:0.68%
cases:9.09%
controls:0.57%
—
—
—
—
—
—
cases:7.14%
controls:0.71%
cases:7.89%
controls:0.81%
5
6
83
874
8
5
80
875
—
—
—
6
6
78
836
6
6
70
738
prednisone; oral
H02AB07 [21602735]
2.2e+00
2.9e+00
—
—
—
2.4e+00
2.3e+00
cases:5.68%
controls:0.68%
cases:9.09%
controls:0.57%
—
—
—
—
—
—
cases:7.14%
controls:0.71%
cases:7.89%
controls:0.81%
5
6
83
874
8
5
80
875
—
—
—
6
6
78
836
6
6
70
738
Normoblasts [#/volume] in Blood
715-3 [3021589]
5.3e-01
7.9e-01
2.4e+00
—
2.3e+00
1.4e+00
1.1e+00
cases:13.64%
controls:8.52%
cases:14.77%
controls:7.27%
cases:17.05%
controls:1.82%
—
—
cases:9.09%
controls:1.02%
cases:22.62%
controls:6.77%
cases:31.58%
controls:13.17%
12
75
76
805
13
64
75
816
15
16
73
864
—
8
9
80
870
19
57
65
785
24
98
52
646
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
1.0e+00
1.7e+00
2.4e+00
—
—
1.7e+00
1.3e+00
cases:15.91%
controls:6.48%
cases:12.50%
controls:2.50%
cases:5.68%
controls:0.57%
—
—
—
—
cases:15.48%
controls:3.33%
cases:23.68%
controls:7.66%
14
57
74
823
11
22
77
858
5
5
83
875
—
—
13
28
71
814
18
57
58
687
Internal Medicine
11 [38004456]
5.2e-01
1.5e+00
—
1.0e+50
2.1e+00
2.0e+00
1.3e+00
cases:28.41%
controls:19.09%
cases:23.86%
controls:6.59%
—
—
cases:15.91%
controls:0.00%
cases:9.09%
controls:1.25%
cases:35.71%
controls:7.01%
cases:44.74%
controls:18.15%
25
168
63
712
21
58
67
822
—
14
0
74
880
8
11
80
868
30
59
54
783
34
135
42
609
Outpatient Visit
OP [9202]
6.5e-01
5.6e-01
1.2e+00
—
2.0e+00
1.4e+00
2.0e+00
cases:80.68%
controls:68.52%
cases:61.36%
controls:47.61%
cases:26.14%
controls:9.66%
—
—
cases:44.32%
controls:10.01%
cases:78.57%
controls:46.67%
cases:96.05%
controls:75.81%
71
603
17
277
54
419
34
461
23
85
65
795
—
39
88
49
791
66
393
18
449
73
564
3
180
Supplier / Service Provider
OMOP5117446 [33004]
-6.7e-01
-4.2e-01
—
—
—
2.9e+00
3.5e+00
cases:17.05%
controls:28.64%
cases:5.68%
controls:8.41%
—
—
—
—
—
—
cases:11.90%
controls:0.71%
cases:23.68%
controls:0.94%
15
252
73
628
5
74
83
806
—
—
—
10
6
74
836
18
7
58
737
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1.7e-01
9.0e-01
2.5e+00
—
1.5e+00
1.1e+00
6.3e-01
cases:30.68%
controls:27.16%
cases:34.09%
controls:17.39%
cases:23.86%
controls:2.61%
—
—
cases:12.50%
controls:2.96%
cases:38.10%
controls:16.75%
cases:50.00%
controls:34.81%
27
239
61
641
30
153
58
727
21
23
67
857
—
11
26
77
853
32
141
52
701
38
259
38
485
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
-3.8e-02
1.2e+00
—
—
2.1e+00
1.4e+00
1.0e+00
cases:13.64%
controls:14.09%
cases:19.32%
controls:6.93%
—
—
—
—
cases:6.82%
controls:0.91%
cases:25.00%
controls:7.36%
cases:38.16%
controls:18.41%
12
124
76
756
17
61
71
819
—
—
6
8
82
871
21
62
63
780
29
137
47
607
Pharmacy visit
OMOP4822462 [581458]
8.6e-01
1.3e+00
9.7e-01
2.7e+00
1.9e+00
1.4e+00
1.0e+50
cases:97.73%
controls:94.77%
cases:94.32%
controls:82.61%
cases:63.64%
controls:39.77%
cases:25.00%
controls:2.16%
cases:82.95%
controls:42.66%
cases:95.24%
controls:82.90%
cases:100.00%
controls:95.83%
86
834
2
46
83
727
5
153
56
350
32
530
22
19
66
861
73
375
15
504
80
698
4
144
76
713
0
31
Laboratory Visit
OMOP4822461 [32036]
5.7e-02
4.1e-01
1.5e+00
2.7e+00
1.2e+00
2.7e-01
6.8e-02
cases:39.77%
controls:38.41%
cases:46.59%
controls:36.70%
cases:36.36%
controls:11.48%
cases:12.50%
controls:0.91%
cases:26.14%
controls:9.67%
cases:44.05%
controls:37.53%
cases:52.63%
controls:50.94%
35
338
53
542
41
323
47
557
32
101
56
779
11
8
77
872
23
85
65
794
37
316
47
526
40
379
36
365
Telephone, letter or other consultation without direct patient contact
ZY020 [2001311600]
-1.0e+50
—
—
—
1.0e+50
2.7e+00
2.3e+00
cases:0.00%
controls:1.02%
—
—
—
—
—
—
cases:6.82%
controls:0.00%
cases:8.33%
controls:0.59%
cases:7.89%
controls:0.81%
0
9
88
871
—
—
—
6
0
82
879
7
5
77
837
6
6
70
738
Emergency Room Visit
ER [9203]
7.4e-01
1.4e+00
1.9e+00
—
1.7e+00
1.7e+00
6.3e-01
cases:45.45%
controls:28.52%
cases:30.68%
controls:10.00%
cases:12.50%
controls:2.05%
—
—
cases:6.82%
controls:1.25%
cases:36.90%
controls:9.74%
cases:42.11%
controls:27.82%
40
251
48
629
27
88
61
792
11
18
77
862
—
6
11
82
868
31
82
53
760
32
207
44
537
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
2.8e-01
6.8e-01
2.6e+00
—
1.7e+00
1.5e+00
8.9e-01
cases:21.59%
controls:17.16%
cases:18.18%
controls:10.11%
cases:19.32%
controls:1.82%
—
—
cases:7.95%
controls:1.48%
cases:33.33%
controls:9.98%
cases:40.79%
controls:22.04%
19
151
69
729
16
89
72
791
17
16
71
864
—
7
13
81
866
28
84
56
758
31
164
45
580
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
2.7e+00
—
—
—
—
2.0e+00
2.1e+00
cases:7.95%
controls:0.57%
—
—
—
—
—
—
—
—
cases:5.95%
controls:0.83%
cases:7.89%
controls:1.08%
7
5
81
875
—
—
—
—
5
7
79
835
6
8
70
736
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
1.0e+00
2.9e+00
—
—
—
—
1.7e+00
cases:7.95%
controls:3.07%
cases:20.45%
controls:1.36%
—
—
—
—
—
—
—
—
cases:14.47%
controls:3.09%
7
27
81
853
18
12
70
868
—
—
—
—
11
23
65
721
Case Management Agency
251B00000X [38004193]
5.1e-02
4.1e-02
9.3e-01
3.6e+00
6.5e-01
3.6e-01
6.0e-01
cases:57.95%
controls:56.70%
cases:52.27%
controls:51.25%
cases:37.50%
controls:19.20%
cases:34.09%
controls:1.36%
cases:31.82%
controls:19.57%
cases:60.71%
controls:51.78%
cases:82.89%
controls:72.58%
51
499
37
381
46
451
42
429
33
169
55
711
30
12
58
868
28
172
60
707
51
436
33
406
63
540
13
204
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
—
1.9e+00
—
—
—
2.3e+00
5.6e-01
—
—
cases:12.50%
controls:2.16%
—
—
—
—
—
—
cases:11.90%
controls:1.31%
cases:13.16%
controls:7.93%
—
11
19
77
861
—
—
—
10
11
74
831
10
59
66
685
Medical doctor
Z2221 [2001311556]
1.1e+00
1.5e+00
—
—
—
2.4e+00
1.7e+00
cases:12.50%
controls:4.66%
cases:7.95%
controls:1.82%
—
—
—
—
—
—
cases:8.33%
controls:0.83%
cases:11.84%
controls:2.42%
11
41
77
839
7
16
81
864
—
—
—
7
7
77
835
9
18
67
726
Short blood count panel - Blood
55429-5 [40758558]
1.1e+00
1.3e+00
2.1e+00
—
—
1.9e+00
1.1e+00
cases:13.64%
controls:5.00%
cases:11.36%
controls:3.30%
cases:7.95%
controls:1.02%
—
—
—
—
cases:15.48%
controls:2.73%
cases:18.42%
controls:7.26%
12
44
76
836
10
29
78
851
7
9
81
871
—
—
13
23
71
819
14
54
62
690
salmeterol and fluticasone
R03AK06 [21603280]
1.8e+00
2.2e+00
—
—
—
1.4e+00
1.3e+00
cases:13.64%
controls:2.50%
cases:9.09%
controls:1.14%
—
—
—
—
—
—
cases:5.95%
controls:1.54%
cases:7.89%
controls:2.28%
12
22
76
858
8
10
80
870
—
—
—
5
13
79
829
6
17
70
727
fluticasone; inhalant
R03BA05 [21603288]
1.6e+00
2.2e+00
—
—
—
1.7e+00
1.3e+00
cases:14.77%
controls:3.41%
cases:12.50%
controls:1.48%
—
—
—
—
—
—
cases:7.14%
controls:1.43%
cases:13.16%
controls:3.90%
13
30
75
850
11
13
77
867
—
—
—
6
12
78
830
10
29
66
715
salbutamol; inhalant
R03AC02 [21603256]
9.3e-01
1.3e+00
—
—
-1.0e+50
1.2e+00
7.1e-01
cases:32.95%
controls:16.25%
cases:20.45%
controls:6.36%
—
—
—
—
cases:0.00%
controls:1.02%
cases:19.05%
controls:6.89%
cases:30.26%
controls:17.61%
29
143
59
737
18
56
70
824
—
—
0
9
88
870
16
58
68
784
23
131
53
613
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
1.4e-01
6.7e-01
2.4e+00
—
—
1.3e+00
9.6e-01
cases:10.23%
controls:8.98%
cases:9.09%
controls:4.89%
cases:6.82%
controls:0.68%
—
—
—
—
cases:11.90%
controls:3.68%
cases:31.58%
controls:15.05%
9
79
79
801
8
43
80
837
6
6
82
874
—
—
10
31
74
811
24
112
52
632
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1.6e-01
3.8e-01
1.7e+00
—
1.6e+00
7.9e-01
3.3e-01
cases:31.82%
controls:28.52%
cases:29.55%
controls:22.27%
cases:19.32%
controls:4.09%
—
—
cases:13.64%
controls:3.19%
cases:39.29%
controls:22.68%
cases:50.00%
controls:41.80%
28
251
60
629
26
196
62
684
17
36
71
844
—
12
28
76
851
33
191
51
651
38
311
38
433
Connective tissue diseases, rheumatoid arthritis and comparable disease
202 [2001600200]
-1.0e+50
—
—
—
1.0e+50
—
3.2e+00
cases:0.00%
controls:0.57%
—
—
—
—
—
—
cases:9.09%
controls:0.00%
—
—
cases:14.47%
controls:0.67%
0
5
88
875
—
—
—
8
0
80
879
—
11
5
65
739
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
3.6e-01
4.8e-01
1.7e+00
—
1.5e+00
6.8e-01
4.0e-01
cases:28.41%
controls:21.70%
cases:25.00%
controls:17.16%
cases:19.32%
controls:4.09%
—
—
cases:12.50%
controls:3.19%
cases:28.57%
controls:16.86%
cases:39.47%
controls:30.38%
25
191
63
689
22
151
66
729
17
36
71
844
—
11
28
77
851
24
142
60
700
30
226
46
518
FEV1/FVC
19926-5 [3011505]
—
—
—
—
—
—
3.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:18.42%
controls:0.94%
—
—
—
—
—
—
14
7
62
737
FVC percent change Respiratory system
69982-7 [42868471]
—
—
—
—
—
—
3.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:18.42%
controls:0.94%
—
—
—
—
—
—
14
7
62
737
FEV1 percent change
69983-5 [42868472]
—
—
—
—
—
—
3.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:18.42%
controls:0.94%
—
—
—
—
—
—
14
7
62
737
FEV1 --post bronchodilation
20155-8 [3023550]
—
—
—
—
—
—
3.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:18.42%
controls:0.94%
—
—
—
—
—
—
14
7
62
737
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
—
—
—
—
—
—
3.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:18.42%
controls:0.94%
—
—
—
—
—
—
14
7
62
737
FEV1
20150-9 [3024653]
—
—
—
—
—
—
3.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:18.42%
controls:0.94%
—
—
—
—
—
—
14
7
62
737
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
—
—
—
—
—
—
3.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:18.42%
controls:0.94%
—
—
—
—
—
—
14
7
62
737
FEV1/FVC --post bronchodilation
69970-2 [42868459]
—
—
—
—
—
—
3.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:18.42%
controls:0.94%
—
—
—
—
—
—
14
7
62
737
Thorax X-ray examination
GD1AA [2001303617]
4.9e-01
1.8e+00
—
1.0e+50
—
1.2e+00
1.4e+00
cases:11.36%
controls:7.27%
cases:10.23%
controls:1.93%
—
—
cases:5.68%
controls:0.00%
—
—
cases:7.14%
controls:2.26%
cases:27.63%
controls:8.60%
10
64
78
816
9
17
79
863
—
5
0
83
880
—
6
19
78
823
21
64
55
680
calcium (different salts in combination); oral
A12AA20 [21600872]
1.8e-01
6.4e-01
—
—
1.7e+00
1.5e+00
1.5e+00
cases:9.09%
controls:7.73%
cases:10.23%
controls:5.68%
—
—
—
—
cases:6.82%
controls:1.25%
cases:19.05%
controls:4.99%
cases:32.89%
controls:10.22%
8
68
80
812
9
50
79
830
—
—
6
11
82
868
16
42
68
800
25
76
51
668
Inpatient Hospital
21 [8717]
1.3e-01
1.5e+00
—
—
—
1.5e+00
8.1e-01
cases:32.95%
controls:30.11%
cases:23.86%
controls:6.82%
—
—
—
—
—
—
cases:28.57%
controls:8.19%
cases:35.53%
controls:19.76%
29
265
59
615
21
60
67
820
—
—
—
24
69
60
773
27
147
49
597
combinations of corticosteroids
D07XB30 [21602188]
1.0e+00
1.9e+00
-1.0e+50
—
—
1.1e+00
9.5e-01
cases:26.14%
controls:11.25%
cases:19.32%
controls:3.41%
cases:0.00%
controls:0.68%
—
—
—
—
cases:11.90%
controls:4.28%
cases:23.68%
controls:10.75%
23
99
65
781
17
30
71
850
0
6
88
874
—
—
10
36
74
806
18
80
58
664
combinations of corticosteroids
D07AB30 [21602118]
1.0e+00
1.9e+00
-1.0e+50
—
—
1.1e+00
9.5e-01
cases:26.14%
controls:11.25%
cases:19.32%
controls:3.41%
cases:0.00%
controls:0.68%
—
—
—
—
cases:11.90%
controls:4.28%
cases:23.68%
controls:10.75%
23
99
65
781
17
30
71
850
0
6
88
874
—
—
10
36
74
806
18
80
58
664
pH of Urine
2756-5 [3015736]
1.9e-01
4.7e-01
—
—
—
1.8e+00
1.1e+00
cases:9.09%
controls:7.61%
cases:5.68%
controls:3.64%
—
—
—
—
—
—
cases:10.71%
controls:2.02%
cases:28.95%
controls:11.69%
8
67
80
813
5
32
83
848
—
—
—
9
17
75
825
22
87
54
657
Ophthalmology
18 [38004463]
5.1e-01
8.2e-01
—
—
—
1.6e+00
1.2e+00
cases:18.18%
controls:11.82%
cases:12.50%
controls:5.91%
—
—
—
—
—
—
cases:21.43%
controls:4.99%
cases:39.47%
controls:16.26%
16
104
72
776
11
52
77
828
—
—
—
18
42
66
800
30
121
46
623
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.84%
controls:0.81%
—
—
—
—
—
—
9
6
67
738
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
—
2.7e+00
—
—
—
—
8.6e-01
—
—
cases:14.77%
controls:1.14%
—
—
—
—
—
—
—
—
cases:7.89%
controls:3.49%
—
13
10
75
870
—
—
—
—
6
26
70
718
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
8.0e-01
2.7e+00
—
—
—
1.8e+00
7.5e-01
cases:7.95%
controls:3.75%
cases:14.77%
controls:1.14%
—
—
—
—
—
—
cases:7.14%
controls:1.31%
cases:7.89%
controls:3.90%
7
33
81
847
13
10
75
870
—
—
—
6
11
78
831
6
29
70
715
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.3e-01
5.3e-01
1.5e+00
—
1.1e+00
5.8e-01
1.8e-01
cases:37.50%
controls:34.43%
cases:42.05%
controls:29.89%
cases:23.86%
controls:6.48%
—
—
cases:17.05%
controls:6.14%
cases:41.67%
controls:28.62%
cases:51.32%
controls:46.91%
33
303
55
577
37
263
51
617
21
57
67
823
—
15
54
73
825
35
241
49
601
39
349
37
395
Leukocytes [#/volume] in Urine
30405-5 [3018095]
-6.2e-02
1.0e+00
—
—
—
1.6e+00
1.1e+00
cases:5.68%
controls:6.02%
cases:6.82%
controls:2.50%
—
—
—
—
—
—
cases:11.90%
controls:2.73%
cases:23.68%
controls:9.54%
5
53
83
827
6
22
82
858
—
—
—
10
23
74
819
18
71
58
673
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
2.6e-01
8.5e-01
2.5e+00
—
—
1.3e+00
4.8e-01
cases:6.82%
controls:5.34%
cases:5.68%
controls:2.50%
cases:6.82%
controls:0.57%
—
—
—
—
cases:7.14%
controls:2.14%
cases:13.16%
controls:8.60%
6
47
82
833
5
22
83
858
6
5
82
875
—
—
6
18
78
824
10
64
66
680
dexamethasone and antiinfectives
S02CA06 [21605178]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.89%
controls:0.67%
—
—
—
—
—
—
6
5
70
739
fusidic acid
D09AA02 [21602265]
8.0e-01
2.5e+00
—
—
—
—
4.9e-01
cases:7.95%
controls:3.75%
cases:7.95%
controls:0.68%
—
—
—
—
—
—
—
—
cases:7.89%
controls:4.97%
7
33
81
847
7
6
81
874
—
—
—
—
6
37
70
707
fusidic acid; ointment
D06AX01 [21602062]
8.0e-01
2.5e+00
—
—
—
—
4.9e-01
cases:7.95%
controls:3.75%
cases:7.95%
controls:0.68%
—
—
—
—
—
—
—
—
cases:7.89%
controls:4.97%
7
33
81
847
7
6
81
874
—
—
—
—
6
37
70
707
fluticasone furoate
R03BA09 [45893496]
1.4e+00
2.4e+00
—
—
—
1.9e+00
1.1e+00
cases:11.36%
controls:3.07%
cases:9.09%
controls:0.91%
—
—
—
—
—
—
cases:7.14%
controls:1.19%
cases:10.53%
controls:3.76%
10
27
78
853
8
8
80
872
—
—
—
6
10
78
832
8
28
68
716
clindamycin; oral, parenteral
J01FF01 [21602985]
1.1e+00
2.4e+00
—
—
—
—
9.9e-01
cases:10.23%
controls:3.64%
cases:7.95%
controls:0.80%
—
—
—
—
—
—
—
—
cases:7.89%
controls:3.09%
9
32
79
848
7
7
81
873
—
—
—
—
6
23
70
721
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
1.4e-01
6.7e-01
2.4e+00
—
—
1.3e+00
9.0e-01
cases:10.23%
controls:8.98%
cases:9.09%
controls:4.89%
cases:6.82%
controls:0.68%
—
—
—
—
cases:11.90%
controls:3.68%
cases:30.26%
controls:15.05%
9
79
79
801
8
43
80
837
6
6
82
874
—
—
10
31
74
811
23
112
53
632
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
7.1e-02
7.2e-01
2.4e+00
—
—
1.3e+00
9.1e-01
cases:9.09%
controls:8.52%
cases:9.09%
controls:4.66%
cases:6.82%
controls:0.68%
—
—
—
—
cases:11.90%
controls:3.68%
cases:30.26%
controls:14.92%
8
75
80
805
8
41
80
839
6
6
82
874
—
—
10
31
74
811
23
111
53
633
Infectious Disease
44 [38004484]
1.3e+00
—
—
—
—
2.4e+00
—
cases:5.68%
controls:1.59%
—
—
—
—
—
—
—
—
cases:5.95%
controls:0.59%
—
—
5
14
83
866
—
—
—
—
5
5
79
837
—
Dermatitis, unspecified
L30.9 [45572271]
1.0e+00
2.2e+00
—
—
—
—
6.3e-01
cases:5.68%
controls:2.16%
cases:6.82%
controls:0.80%
—
—
—
—
—
—
—
—
cases:6.58%
controls:3.63%
5
19
83
861
6
7
82
873
—
—
—
—
5
27
71
717
doxycycline; oral, parenteral
J01AA02 [21602800]
9.3e-01
1.2e+00
—
—
—
8.5e-01
5.1e-01
cases:37.50%
controls:19.20%
cases:18.18%
controls:6.36%
—
—
—
—
—
—
cases:10.71%
controls:4.87%
cases:25.00%
controls:16.67%
33
169
55
711
16
56
72
824
—
—
—
9
41
75
801
19
124
57
620
prednisolone
S01BA04 [21603621]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.21%
controls:1.21%
—
—
—
—
—
—
7
9
69
735
prednisolone
S03BA02 [21605202]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.21%
controls:1.21%
—
—
—
—
—
—
7
9
69
735
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
—
—
—
—
—
2.1e+00
2.7e-01
—
—
—
—
—
—
—
—
—
—
cases:7.14%
controls:0.95%
cases:6.58%
controls:5.11%
—
—
—
—
—
6
8
78
834
5
38
71
706
dexamethasone
S03BA01 [21605201]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:15.79%
controls:2.28%
—
—
—
—
—
—
12
17
64
727
dexamethasone
S01BA01 [21603618]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:15.79%
controls:2.28%
—
—
—
—
—
—
12
17
64
727
fexofenadine; oral
R06AX26 [21603525]
2.1e+00
—
—
—
—
—
—
cases:6.82%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
82
872
—
—
—
—
—
—
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
2.1e+00
—
—
—
—
2.0e+00
1.7e+00
cases:9.09%
controls:1.25%
—
—
—
—
—
—
—
—
cases:7.14%
controls:1.07%
cases:9.21%
controls:1.75%
8
11
80
869
—
—
—
—
6
9
78
833
7
13
69
731
DNA double strand Ab [Units/volume] in Serum
5130-0 [3023420]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.89%
controls:1.08%
—
—
—
—
—
—
6
8
70
736
Erysipelas
A46 [45561706]
2.0e+00
—
—
—
—
—
—
cases:7.95%
controls:1.14%
—
—
—
—
—
—
—
—
—
—
—
—
7
10
81
870
—
—
—
—
—
—
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
—
-1.0e+50
—
—
—
1.9e+00
7.8e-01
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
cases:8.33%
controls:1.31%
cases:7.89%
controls:3.76%
—
0
11
88
869
—
—
—
7
11
77
831
6
28
70
716
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
—
1.2e+00
—
—
—
1.8e+00
2.2e-01
—
—
cases:5.68%
controls:1.70%
—
—
—
—
—
—
cases:9.52%
controls:1.66%
cases:9.21%
controls:7.53%
—
5
15
83
865
—
—
—
8
14
76
828
7
56
69
688
dexamethasone and antiinfectives
S03CA01 [21605206]
1.2e+00
—
—
—
—
—
1.8e+00
cases:5.68%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:1.88%
5
16
83
864
—
—
—
—
—
8
14
68
730
folic acid
V04CX02 [715877]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.84%
controls:2.15%
—
—
—
—
—
—
9
16
67
728
folic acid; oral, parenteral
B03BB01 [21601129]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.84%
controls:2.15%
—
—
—
—
—
—
9
16
67
728
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
2.2e-01
2.3e-01
1.8e+00
—
1.0e+00
7.7e-01
4.2e-01
cases:26.14%
controls:22.16%
cases:21.59%
controls:17.95%
cases:17.05%
controls:3.30%
—
—
cases:9.09%
controls:3.41%
cases:30.95%
controls:17.22%
cases:40.79%
controls:31.18%
23
195
65
685
19
158
69
722
15
29
73
851
—
8
30
80
849
26
145
58
697
31
232
45
512
Pain in limb
M79.6 [45587063]
8.4e-01
—
—
—
—
1.7e+00
8.0e-01
cases:12.50%
controls:5.80%
—
—
—
—
—
—
—
—
cases:13.10%
controls:2.61%
cases:19.74%
controls:9.95%
11
51
77
829
—
—
—
—
11
22
73
820
15
74
61
670
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
—
1.1e+00
—
—
—
1.7e+00
3.6e-01
—
—
cases:5.68%
controls:2.05%
—
—
—
—
—
—
cases:10.71%
controls:2.14%
cases:11.84%
controls:8.60%
—
5
18
83
862
—
—
—
9
18
75
824
9
64
67
680
Physiotherapy
R4110 [2001310233]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.16%
controls:2.69%
—
—
—
—
—
—
10
20
66
724
pantoprazole; oral, parenteral
A02BC02 [21600097]
5.1e-01
7.1e-01
—
—
1.7e+00
6.2e-01
6.1e-01
cases:21.59%
controls:14.20%
cases:17.05%
controls:9.20%
—
—
—
—
cases:10.23%
controls:2.05%
cases:13.10%
controls:7.48%
cases:27.63%
controls:17.20%
19
125
69
755
15
81
73
799
—
—
9
18
79
861
11
63
73
779
21
128
55
616
Bacteria [Presence] in Urine
87829-8 [36304419]
—
—
—
—
—
1.7e+00
2.4e-01
—
—
—
—
—
—
—
—
—
—
cases:9.52%
controls:1.90%
cases:9.21%
controls:7.39%
—
—
—
—
—
8
16
76
826
7
55
69
689
roxithromycin; oral
J01FA06 [21602974]
7.2e-01
—
—
—
—
—
1.7e+00
cases:9.09%
controls:4.66%
—
—
—
—
—
—
—
—
—
—
cases:14.47%
controls:3.09%
8
41
80
839
—
—
—
—
—
11
23
65
721
antibiotics in combination with other drugs
S01AA20 [21603571]
1.0e+00
1.6e+00
—
—
—
1.4e+00
9.6e-01
cases:17.05%
controls:6.82%
cases:10.23%
controls:2.16%
—
—
—
—
—
—
cases:7.14%
controls:1.78%
cases:15.79%
controls:6.72%
15
60
73
820
9
19
79
861
—
—
—
6
15
78
827
12
50
64
694
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
-5.2e-02
6.8e-01
—
—
—
1.6e+00
3.3e-01
cases:6.82%
controls:7.16%
cases:5.68%
controls:2.95%
—
—
—
—
—
—
cases:11.90%
controls:2.73%
cases:13.16%
controls:9.81%
6
63
82
817
5
26
83
854
—
—
—
10
23
74
819
10
73
66
671
omeprazole; oral, parenteral
A02BC01 [21600096]
3.4e-01
—
—
—
—
1.7e+00
1.6e+00
cases:5.68%
controls:4.09%
—
—
—
—
—
—
—
—
cases:5.95%
controls:1.19%
cases:13.16%
controls:3.09%
5
36
83
844
—
—
—
—
5
10
79
832
10
23
66
721
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.9e-01
2.5e-01
1.5e+00
—
9.6e-01
6.2e-01
2.2e-01
cases:35.23%
controls:31.02%
cases:29.55%
controls:24.55%
cases:20.45%
controls:5.23%
—
—
cases:11.36%
controls:4.66%
cases:38.10%
controls:24.94%
cases:47.37%
controls:41.94%
31
273
57
607
26
216
62
664
18
46
70
834
—
10
41
78
838
32
210
52
632
36
312
40
432
MCH [Entitic mass]
28539-5 [3035941]
1.3e-01
5.4e-01
1.5e+00
—
1.1e+00
5.8e-01
1.8e-01
cases:37.50%
controls:34.43%
cases:42.05%
controls:29.77%
cases:23.86%
controls:6.36%
—
—
cases:15.91%
controls:6.03%
cases:41.67%
controls:28.62%
cases:51.32%
controls:46.91%
33
303
55
577
37
262
51
618
21
56
67
824
—
14
53
74
826
35
241
49
601
39
349
37
395
Pulmonary Disease
29 [38004472]
6.9e-01
1.5e+00
—
—
—
1.1e+00
9.4e-01
cases:17.05%
controls:9.32%
cases:14.77%
controls:3.64%
—
—
—
—
—
—
cases:9.52%
controls:3.33%
cases:19.74%
controls:8.74%
15
82
73
798
13
32
75
848
—
—
—
8
28
76
814
15
65
61
679
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.3e-01
5.4e-01
1.5e+00
—
1.1e+00
5.8e-01
1.8e-01
cases:37.50%
controls:34.43%
cases:42.05%
controls:29.77%
cases:23.86%
controls:6.48%
—
—
cases:15.91%
controls:6.03%
cases:41.67%
controls:28.62%
cases:51.32%
controls:46.91%
33
303
55
577
37
262
51
618
21
57
67
823
—
14
53
74
826
35
241
49
601
39
349
37
395
Platelets [#/volume] in Blood
26515-7 [3007461]
1.3e-01
5.0e-01
1.5e+00
—
1.1e+00
5.9e-01
1.7e-01
cases:37.50%
controls:34.43%
cases:40.91%
controls:29.55%
cases:23.86%
controls:6.48%
—
—
cases:15.91%
controls:6.03%
cases:41.67%
controls:28.38%
cases:51.32%
controls:47.04%
33
303
55
577
36
260
52
620
21
57
67
823
—
14
53
74
826
35
239
49
603
39
350
37
394
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.2e-01
5.4e-01
1.5e+00
—
1.1e+00
5.8e-01
1.7e-01
cases:37.50%
controls:34.66%
cases:42.05%
controls:29.77%
cases:23.86%
controls:6.48%
—
—
cases:15.91%
controls:6.14%
cases:41.67%
controls:28.62%
cases:51.32%
controls:47.04%
33
305
55
575
37
262
51
618
21
57
67
823
—
14
54
74
825
35
241
49
601
39
350
37
394
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.3e-01
5.4e-01
1.5e+00
—
1.1e+00
5.8e-01
1.7e-01
cases:37.50%
controls:34.43%
cases:42.05%
controls:29.77%
cases:23.86%
controls:6.48%
—
—
cases:15.91%
controls:6.14%
cases:41.67%
controls:28.62%
cases:51.32%
controls:47.04%
33
303
55
577
37
262
51
618
21
57
67
823
—
14
54
74
825
35
241
49
601
39
350
37
394
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.3e-01
5.4e-01
1.5e+00
—
1.1e+00
5.8e-01
1.7e-01
cases:37.50%
controls:34.43%
cases:42.05%
controls:29.77%
cases:23.86%
controls:6.48%
—
—
cases:15.91%
controls:6.03%
cases:41.67%
controls:28.62%
cases:51.32%
controls:47.04%
33
303
55
577
37
262
51
618
21
57
67
823
—
14
53
74
826
35
241
49
601
39
350
37
394
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
1.8e-01
4.7e-01
1.5e+00
—
1.2e+00
4.4e-01
1.5e-01
cases:29.55%
controls:26.02%
cases:30.68%
controls:21.59%
cases:18.18%
controls:4.77%
—
—
cases:11.36%
controls:3.87%
cases:28.57%
controls:20.55%
cases:36.84%
controls:33.47%
26
229
62
651
27
190
61
690
16
42
72
838
—
10
34
78
845
24
173
60
669
28
249
48
495
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
2.9e-01
1.5e+00
—
—
—
1.2e+00
6.7e-01
cases:11.36%
controls:8.75%
cases:11.36%
controls:2.84%
—
—
—
—
—
—
cases:5.95%
controls:1.78%
cases:15.79%
controls:8.74%
10
77
78
803
10
25
78
855
—
—
—
5
15
79
827
12
65
64
679
Outpatient Hospital
22 [8756]
1.9e-01
7.6e-01
—
—
—
1.4e+00
7.7e-01
cases:27.27%
controls:23.64%
cases:11.36%
controls:5.68%
—
—
—
—
—
—
cases:19.05%
controls:5.46%
cases:28.95%
controls:15.86%
24
208
64
672
10
50
78
830
—
—
—
16
46
68
796
22
118
54
626
fluticasone furoate; nasal
R01AD12 [21605053]
4.7e-01
1.4e+00
—
—
—
7.0e-01
8.2e-01
cases:17.05%
controls:11.36%
cases:14.77%
controls:4.09%
—
—
—
—
—
—
cases:7.14%
controls:3.68%
cases:19.74%
controls:9.81%
15
100
73
780
13
36
75
844
—
—
—
6
31
78
811
15
73
61
671
fluticasone; nasal
R01AD08 [21605050]
4.7e-01
1.4e+00
—
—
—
7.0e-01
8.2e-01
cases:17.05%
controls:11.36%
cases:14.77%
controls:4.09%
—
—
—
—
—
—
cases:7.14%
controls:3.68%
cases:19.74%
controls:9.81%
15
100
73
780
13
36
75
844
—
—
—
6
31
78
811
15
73
61
671
montelukast; oral
R03DC03 [21603356]
1.4e+00
1.4e+00
—
—
—
1.2e+00
1.1e+00
cases:15.91%
controls:4.66%
cases:7.95%
controls:2.16%
—
—
—
—
—
—
cases:7.14%
controls:2.26%
cases:10.53%
controls:3.63%
14
41
74
839
7
19
81
861
—
—
—
6
19
78
823
8
27
68
717
General Practice
1 [38004446]
2.4e-01
2.3e-01
—
—
-1.0e+50
1.3e+00
5.1e-01
cases:13.64%
controls:11.02%
cases:5.68%
controls:4.55%
—
—
—
—
cases:0.00%
controls:0.57%
cases:14.29%
controls:4.28%
cases:18.42%
controls:11.96%
12
97
76
783
5
40
83
840
—
—
0
5
88
874
12
36
72
806
14
89
62
655
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:18.42%
controls:6.45%
—
—
—
—
—
—
14
48
62
696
Scheduled procedure
ZXD10 [2001311387]
1.1e+00
—
—
—
—
1.9e+00
1.1e+00
cases:15.91%
controls:5.80%
—
—
—
—
—
—
—
—
cases:7.14%
controls:1.19%
cases:7.89%
controls:2.82%
14
51
74
829
—
—
—
—
6
10
78
832
6
21
70
723
fluconazole; oral, parenteral
J02AC01 [21603080]
1.0e+00
1.5e+00
—
—
—
1.4e+00
9.1e-01
cases:21.59%
controls:9.09%
cases:9.09%
controls:2.16%
—
—
—
—
—
—
cases:8.33%
controls:2.14%
cases:17.11%
controls:7.66%
19
80
69
800
8
19
80
861
—
—
—
7
18
77
824
13
57
63
687
Headache
R51.80 [2000503603]
1.1e+00
—
—
—
—
—
1.4e+00
cases:5.68%
controls:2.05%
—
—
—
—
—
—
—
—
—
—
cases:6.58%
controls:1.75%
5
18
83
862
—
—
—
—
—
5
13
71
731
Ankylosing spondylitis
M45 [45591841]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
88
875
—
—
—
—
—
—
insulin lispro; parenteral
A10AB04 [21600718]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:2.39%
cases:0.00%
controls:1.93%
—
—
—
—
cases:0.00%
controls:0.57%
cases:0.00%
controls:1.90%
cases:0.00%
controls:2.15%
0
21
88
859
0
17
88
863
—
—
0
5
88
874
0
16
84
826
0
16
76
728
More than three and less than five hours
ZXE20 [2001311408]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
88
865
—
—
—
—
—
—
Risk factor NOS
A23 [2002000158]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:2.55%
0
9
88
871
—
—
—
—
0
5
84
837
0
19
76
725
Treatment of reopened or infected surgical wound
SPAT1144 [2001700245]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
5
88
875
—
—
—
—
—
Teaching
WZC30 [2001310891]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
—
0
12
88
868
—
—
—
—
—
hydrocortisone and antiinfectives
S02CA03 [21605175]
—
2.0e+00
—
—
—
—
1.7e+00
—
—
cases:5.68%
controls:0.80%
—
—
—
—
—
—
—
—
cases:9.21%
controls:1.75%
—
5
7
83
873
—
—
—
—
7
13
69
731
Pulp capping
SGC10 [2001310393]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.48%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
0
13
88
867
—
—
—
—
—
0
5
76
739
Burn-out
Z73.0 [45576177]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
0
8
88
872
—
—
—
—
—
0
5
76
739
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
5
88
875
—
—
—
—
—
Neurology
13 [38004458]
2.5e-01
7.6e-01
—
—
—
1.2e+00
5.3e-01
cases:12.50%
controls:10.00%
cases:7.95%
controls:3.86%
—
—
—
—
—
—
cases:13.10%
controls:4.39%
cases:15.79%
controls:9.95%
11
88
77
792
7
34
81
846
—
—
—
11
37
73
805
12
74
64
670
Vascular Surgery
77 [38004496]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
0
6
88
874
—
—
—
0
7
84
835
—
dexamethasone; oral, parenteral
H02AB02 [21602730]
—
—
—
—
—
—
7.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.58%
controls:3.23%
—
—
—
—
—
—
5
24
71
720
long-acting sulfonamides - combinations
J01ED20 [21602959]
1.1e+00
—
—
—
—
—
—
cases:5.68%
controls:2.05%
—
—
—
—
—
—
—
—
—
—
—
—
5
18
83
862
—
—
—
—
—
—
Monitored bed care
WX892 [2001310850]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
88
875
—
—
—
—
—
—
antibiotics in combination with corticosteroids
D01AA20 [21601918]
1.1e+00
—
—
—
—
—
—
cases:5.68%
controls:1.93%
—
—
—
—
—
—
—
—
—
—
—
—
5
17
83
863
—
—
—
—
—
—
Hypokalaemia
E87.6 [45537991]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
6
76
738
chlorhexidine
D09AA12 [21602275]
8.5e-01
—
—
—
—
—
—
cases:5.68%
controls:2.50%
—
—
—
—
—
—
—
—
—
—
—
—
5
22
83
858
—
—
—
—
—
—
Atrial fibrillation and atrial flutter, unspecified
I48.9 [45755409]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.08%
—
—
—
—
—
—
0
8
76
736
Sciatica
M54.3 [45586994]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
88
872
—
—
—
—
—
—
Acute conjunctivitis, unspecified
H10.3 [45566958]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
6
76
738
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.88%
—
—
—
—
—
—
0
14
76
730
Potassium [Moles/volume] in Arterial blood
32713-0 [3043409]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
76
739
Lumbago with sciatica
M54.4 [45553205]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
0
5
88
874
—
—
Neutrophils [#/volume] in Blood
26499-4 [3017732]
-1.0e+50
—
—
—
—
—
1.5e+00
cases:0.00%
controls:1.14%
—
—
—
—
—
—
—
—
—
—
cases:9.21%
controls:2.15%
0
10
88
870
—
—
—
—
—
7
16
69
728
Insertion of (intrauterine) contraceptive device
Z30.1 [45537626]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:1.75%
—
0
5
88
875
—
—
—
0
5
84
837
0
13
76
731
carbimazole; oral
H03BB01 [21602765]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
5
88
875
—
—
—
—
—
Campylobacter sp identified in Tissue by Organism specific culture
20740-7 [3006418]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
6
76
738
Single live birth
Z37.0 [45571346]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
7
76
737
brinzolamide, combinations
S01EC54 [45893490]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
0
5
88
875
—
—
—
—
—
0
5
76
739
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
4.0e-01
2.4e-01
—
—
—
2.4e-01
-9.2e-02
cases:30.68%
controls:22.95%
cases:20.45%
controls:16.82%
—
—
—
—
—
—
cases:19.05%
controls:15.56%
cases:31.58%
controls:33.60%
27
202
61
678
18
148
70
732
—
—
—
16
131
68
711
24
250
52
494
theophylline; oral, parenteral, rectal
R03DA04 [21603332]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
76
739
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.84%
controls:2.96%
—
—
—
—
—
—
9
22
67
722
Skin texture symptom/complaint
S21 [2002000986]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
0
5
84
837
—
Assessment of need for rehabilitation and/or rehabilitation plan
SPAT1220 [2001700321]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
76
739
budesonide; inhalant
R03BA02 [21603285]
1.7e-01
—
-1.0e+50
—
—
—
—
cases:6.82%
controls:5.80%
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
6
51
82
829
—
0
9
88
871
—
—
—
—
Wrist X-ray examination
ND1AA [2001307576]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
0
5
88
875
—
—
—
—
—
0
7
76
737
Paranasal sinuses X-ray examination without contrast
DM1AA [2001301740]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
88
875
—
—
—
—
—
—
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
1.2e+00
—
—
—
—
1.3e+00
8.9e-01
cases:13.64%
controls:4.43%
—
—
—
—
—
—
—
—
cases:7.14%
controls:2.02%
cases:11.84%
controls:5.24%
12
39
76
841
—
—
—
—
6
17
78
825
9
39
67
705
Knee symptom/complaint
L15 [2002000639]
—
—
—
—
—
—
9.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.89%
controls:3.23%
—
—
—
—
—
—
6
24
70
720
Simple examination of mouth
SAA01 [2001310274]
1.7e-01
3.1e-01
—
—
—
3.2e-01
1.9e-01
cases:26.14%
controls:22.95%
cases:13.64%
controls:10.34%
—
—
—
—
—
—
cases:14.29%
controls:10.81%
cases:32.89%
controls:28.90%
23
202
65
678
12
91
76
789
—
—
—
12
91
72
751
25
215
51
529
Uroflowmetry
44856007 [4261340]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
0
6
84
836
—
Allergic rhinitis, unspecified
J30.4 [45548110]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
88
875
—
—
—
—
—
—
Maternal care for breech presentation
O32.1 [45606580]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
88
874
—
—
—
—
—
—
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
4.1e-01
2.8e-01
—
—
—
4.4e-01
1.4e-01
cases:25.00%
controls:18.18%
cases:15.91%
controls:12.50%
—
—
—
—
—
—
cases:16.67%
controls:11.40%
cases:30.26%
controls:27.42%
22
160
66
720
14
110
74
770
—
—
—
14
96
70
746
23
204
53
540
Pap smear
SPAT1193 [2001700294]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
0
5
88
875
—
—
—
—
0
12
76
732
furosemide; oral, parenteral
C03CA01 [21601518]
4.4e-01
—
—
—
—
—
—
cases:5.68%
controls:3.75%
—
—
—
—
—
—
—
—
—
—
—
—
5
33
83
847
—
—
—
—
—
—
Hemoglobin.gastrointestinal [Presence] in Stool
2335-8 [3016251]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
0
5
84
837
—
Anoscopy
UJH02 [2001305182]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
6
76
738
finasteride; oral
G04CB01 [21602675]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
88
875
—
—
—
—
—
—
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.58%
controls:1.08%
—
—
—
—
—
—
5
8
71
736
testosterone; oral, parenteral, rectal, sublingual, transdermal
G03BA03 [21602510]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
6
76
738
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
—
-1.0e+50
—
—
—
—
1.8e+00
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
cases:7.89%
controls:1.34%
—
0
9
88
871
—
—
—
—
6
10
70
734
Person consulting for explanation of investigation findings
Z71.2 [45552100]
1.1e+00
—
—
—
—
—
4.1e-01
cases:9.09%
controls:3.30%
—
—
—
—
—
—
—
—
—
—
cases:9.21%
controls:6.32%
8
29
80
851
—
—
—
—
—
7
47
69
697
Streptococcal tonsillitis
J03.0 [45601114]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
88
873
—
—
—
—
—
—
dexamethasone
C05AA09 [21601613]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.58%
controls:1.48%
—
—
—
—
—
—
5
11
71
733
dexrabeprazole
A02BC07 [45893509]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
88
870
—
—
—
—
—
—
nifedipine; oral, parenteral
C08CA05 [21601751]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
88
875
—
—
—
—
—
—
Nursing episode
950 [44777714]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
88
872
—
—
—
—
—
—
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
—
—
—
—
—
—
-4.4e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.58%
controls:6.85%
—
—
—
—
—
—
5
51
71
693
clonazepam; oral, parenteral
N03AE01 [21604415]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.91%
cases:0.00%
controls:1.02%
—
—
—
—
—
—
cases:0.00%
controls:0.95%
cases:0.00%
controls:1.61%
0
8
88
872
0
9
88
871
—
—
—
0
8
84
834
0
12
76
732
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
—
—
—
—
—
—
5.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.58%
controls:3.90%
—
—
—
—
—
—
5
29
71
715
Concise certificate
WZA00 [2001310879]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
88
874
—
—
—
—
—
—
Three-surface restoration
SFA30 [2001310360]
1.4e-01
—
—
—
—
—
4.5e-03
cases:10.23%
controls:8.98%
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:10.48%
9
79
79
801
—
—
—
—
—
8
78
68
666
Monitoring of normal pregnancy
SPAT1196 [2001700297]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
88
870
—
—
—
—
—
—
Hypertrophy of breast
N62 [45577538]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
0
5
88
875
—
—
—
—
0
5
76
739
mometasone
D07AC13 [21602132]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
—
—
—
—
0
13
84
829
—
Pain general/multiple sites
A01 [2002000142]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
88
873
—
—
—
—
—
—
Yersinia sp identified in Stool by Organism specific culture
28549-4 [3014765]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
0
6
88
874
—
—
—
—
—
0
6
76
738
Insertion of intrauterine device
TLC00 [2001306647]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
0
5
84
837
—
enalapril and diuretics
C09BA02 [21601804]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
0
6
88
874
—
—
—
—
Hip symptom/complaint
L13 [2002000637]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
0
7
88
873
—
—
—
—
—
Calprotectin [Mass/mass] in Stool
38445-3 [3048689]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.89%
controls:2.69%
—
—
—
—
—
—
6
20
70
724
Streptococcus agalactiae Ag [Presence] in Vaginal fluid
40784-1 [3042206]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
6
76
738
apixaban; oral
B01AF02 [43534762]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.68%
cases:0.00%
controls:0.68%
—
—
—
—
—
—
cases:0.00%
controls:1.19%
cases:0.00%
controls:2.69%
0
6
88
874
0
6
88
874
—
—
—
0
10
84
832
0
20
76
724
Procedure duration 10 to 19 minutes
ZXE02 [2001311396]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
88
872
—
—
—
—
—
—
valaciclovir; oral
J05AB11 [21603137]
8.1e-01
—
—
—
—
—
—
cases:5.68%
controls:2.61%
—
—
—
—
—
—
—
—
—
—
—
—
5
23
83
857
—
—
—
—
—
—
Hemoglobin [Mass/volume] in Venous blood
30350-3 [3004119]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
0
6
84
836
—
miconazole
D01AC02 [21601921]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
76
739
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
—
—
—
—
—
—
-5.5e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.21%
controls:9.68%
—
—
—
—
—
—
7
72
69
672
hypromellose
S01KA02 [21605115]
1.1e+00
—
—
—
—
—
1.2e+00
cases:6.82%
controls:2.39%
—
—
—
—
—
—
—
—
—
—
cases:9.21%
controls:2.96%
6
21
82
859
—
—
—
—
—
7
22
69
722
glucagon; nasal, parenteral
H04AA01 [21602778]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.80%
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
0
7
88
873
0
5
88
875
—
—
—
—
0
6
76
738
Other specified intervertebral disc degeneration
M51.3 [45591865]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
0
12
76
732
Insertion or removal of intrauterine contraceptive device
SPAT1190 [2001700291]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
0
5
88
875
—
—
—
—
—
0
5
76
739
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
88
871
—
—
—
—
—
—
Psychological sympt/compl other
P29 [2002000823]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
88
870
—
—
—
—
—
—
propranolol; oral, parenteral
C07AA05 [21601670]
—
—
—
—
—
—
3.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.58%
controls:4.70%
—
—
—
—
—
—
5
35
71
709
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.14%
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
0
10
88
870
0
5
88
875
—
—
—
—
—
Recurrent depressive disorder, current episode severe without psychotic symptoms
F33.2 [45547705]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:0.67%
—
—
—
—
—
0
6
84
836
0
5
76
739
Knee and lower leg extensive MRI examination with high intensity magnet
NG1CG [2001308063]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
88
874
—
—
—
—
—
—
pseudoephedrine, combinations; oral
R01BA52 [21603213]
1.7e-01
1.1e+00
-1.0e+50
—
—
—
4.3e-01
cases:15.91%
controls:13.75%
cases:13.64%
controls:4.77%
cases:0.00%
controls:0.57%
—
—
—
—
—
—
cases:18.42%
controls:12.77%
14
121
74
759
12
42
76
838
0
5
88
875
—
—
—
14
95
62
649
ibuprofen
R02AX02 [1588667]
4.4e-01
4.0e-01
8.5e-01
—
1.5e+00
6.7e-01
5.9e-01
cases:48.86%
controls:38.18%
cases:25.00%
controls:18.30%
cases:5.68%
controls:2.50%
—
—
cases:7.95%
controls:1.82%
cases:28.57%
controls:16.98%
cases:51.32%
controls:36.96%
43
336
45
544
22
161
66
719
5
22
83
858
—
7
16
81
863
24
143
60
699
39
275
37
469
Diabetes insulin dependent
T89 [2002001130]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.48%
cases:0.00%
controls:0.80%
—
—
—
—
—
—
cases:0.00%
controls:1.07%
cases:0.00%
controls:1.21%
0
13
88
867
0
7
88
873
—
—
—
0
9
84
833
0
9
76
735
Occupational therapy
R4120 [2001310234]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
88
873
—
—
—
—
—
—
Spondylolisthesis
M43.1 [45606219]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
0
8
88
872
—
—
—
—
—
0
6
76
738
Dry eye syndrome
H04.10 [2000502254]
—
-1.0e+50
—
—
—
—
1.4e+00
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
cases:7.89%
controls:2.02%
—
0
6
88
874
—
—
—
—
6
15
70
729
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
0
6
88
874
—
—
—
—
—
lactulose; oral
A06AD11 [21600571]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.68%
cases:0.00%
controls:0.57%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
0
6
88
874
0
5
88
875
—
—
—
0
6
84
836
—
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
-1.0e+50
-1.0e+50
—
—
—
—
9.0e-01
cases:0.00%
controls:3.18%
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
cases:10.53%
controls:4.57%
0
28
88
852
0
16
88
864
—
—
—
—
8
34
68
710
Sex hormone binding globulin [Moles/volume] in Serum or Plasma
13967-5 [3004248]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
76
739
Gonarthrosis, unspecified
M17.9 [45606128]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
88
873
—
—
—
—
—
—
Acute tonsillitis, unspecified
J03.9 [45576942]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
88
874
—
—
—
—
—
—
Complicated migraine
G43.3 [45576576]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
6
76
738
ciclesonide; inhalant
R03BA08 [21603291]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
0
6
88
873
—
—
piroxicam; ointment
M02AA07 [21604043]
8.7e-01
—
—
—
—
—
9.5e-01
cases:11.36%
controls:5.11%
—
—
—
—
—
—
—
—
—
—
cases:9.21%
controls:3.76%
10
45
78
835
—
—
—
—
—
7
28
69
716
eletriptan; oral
N02CC06 [21604381]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
0
5
88
875
—
—
—
—
—
0
7
76
737
Other dorsalgia
M54.8 [45538790]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
88
875
—
—
—
—
—
—
acetylsalicylic acid; oral
B01AC06 [21600991]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.02%
cases:0.00%
controls:0.80%
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
0
9
88
871
0
7
88
873
—
—
—
0
8
84
834
—
Heartburn
R12 [45539318]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
88
873
—
—
—
—
—
—
Gastro-oesophageal reflux disease without oesophagitis
K21.9 [45538509]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
88
868
—
—
—
—
—
—
Atrial fibrillation and flutter
I48 [45596206]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.36%
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
0
12
88
868
—
—
—
0
13
84
829
—
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
1.0e+00
—
—
—
—
—
—
cases:11.36%
controls:4.43%
—
—
—
—
—
—
—
—
—
—
—
—
10
39
78
841
—
—
—
—
—
—
Issue of repeat prescription
Z76.0 [45542456]
1.2e+00
—
—
—
—
—
2.4e-01
cases:5.68%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
cases:6.58%
controls:5.24%
5
16
83
864
—
—
—
—
—
5
39
71
705
Muscle pain
L18 [2002000642]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
76
739
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.36%
—
—
—
—
—
—
cases:0.00%
controls:1.31%
—
—
—
0
12
88
868
—
—
—
0
11
84
831
—
Infiltration anesthesia
WX110 [2001310767]
-1.8e-01
-2.3e-01
—
—
-1.0e+50
1.0e-01
4.0e-01
cases:15.91%
controls:18.52%
cases:6.82%
controls:8.41%
—
—
—
—
cases:0.00%
controls:1.02%
cases:8.33%
controls:7.60%
cases:28.95%
controls:21.37%
14
163
74
717
6
74
82
806
—
—
0
9
88
870
7
64
77
778
22
159
54
585
azelastine; nasal
R01AC03 [21605035]
5.2e-01
—
-1.0e+50
—
—
—
—
cases:7.95%
controls:4.89%
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
7
43
81
837
—
0
6
88
874
—
—
—
—
paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
0
10
88
870
—
—
—
0
10
84
832
—
Risk factor cardiovascular disease
K22 [2002000551]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
88
874
—
—
—
—
—
—
Other allergic rhinitis
J30.3 [45538477]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
76
739
Surface analgesia on skin or mucosa
WX105 [2001310765]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.91%
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.48%
0
8
88
872
0
6
88
874
—
—
—
—
0
11
76
733
Supraglottic ventilation device
WX702 [2001310818]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
76
739
Acute pharyngitis
J02 [45557615]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
88
872
—
—
—
—
—
—
losartan and diuretics
C09DA01 [21601834]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
0
6
88
874
—
—
—
—
Contraception intrauterine
W12 [2002001212]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.25%
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
0
11
88
869
0
5
88
875
—
—
—
—
—
lansoprazole; oral
A02BC03 [21600098]
2.9e-01
—
—
—
—
—
—
cases:5.68%
controls:4.32%
—
—
—
—
—
—
—
—
—
—
—
—
5
38
83
842
—
—
—
—
—
—
Nephrology
39 [38004479]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.07%
cases:0.00%
controls:1.34%
0
7
88
873
—
—
—
—
0
9
84
833
0
10
76
734
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
2.4e-01
4.7e-01
—
—
—
8.5e-01
3.2e-01
cases:9.09%
controls:7.27%
cases:7.95%
controls:5.11%
—
—
—
—
—
—
cases:10.71%
controls:4.87%
cases:15.79%
controls:11.96%
8
64
80
816
7
45
81
835
—
—
—
9
41
75
801
12
89
64
655
C peptide [Moles/volume] in Serum or Plasma --fasting
42180-0 [3032836]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
88
875
—
—
—
—
—
—
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
290 [2001600222]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
88
874
—
—
—
—
—
—
Glucose tolerance 2 hours panel - Serum or Plasma
72171-2 [43054914]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
0
9
84
833
—
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
1.6e+00
—
—
—
—
—
—
cases:6.82%
controls:1.48%
—
—
—
—
—
—
—
—
—
—
—
—
6
13
82
867
—
—
—
—
—
—
Opening and preparing the root canals, complicated
SGA03 [2001310381]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
88
868
—
—
—
—
—
—
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
6.3e-03
-4.3e-01
-1.0e+50
—
-1.0e+50
-4.6e-01
2.8e-02
cases:23.86%
controls:23.75%
cases:11.36%
controls:16.48%
cases:0.00%
controls:1.59%
—
—
cases:0.00%
controls:1.37%
cases:10.71%
controls:15.91%
cases:38.16%
controls:37.50%
21
209
67
671
10
145
78
735
0
14
88
866
—
0
12
88
867
9
134
75
708
29
279
47
465
Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
21613-5 [3006093]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.55%
—
0
8
88
872
—
—
—
—
0
19
76
725
Stress incontinence
N39.3 [45539046]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
88
867
—
—
—
—
—
—
Office Visit
OMOP4822458 [581477]
6.0e-01
—
—
—
—
1.3e+00
1.1e+00
cases:15.91%
controls:9.43%
—
—
—
—
—
—
—
—
cases:7.14%
controls:2.14%
cases:14.47%
controls:5.38%
14
83
74
797
—
—
—
—
6
18
78
824
11
40
65
704
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
-3.8e-01
9.2e-01
—
—
—
—
-7.6e-02
cases:6.82%
controls:9.66%
cases:6.82%
controls:2.84%
—
—
—
—
—
—
—
—
cases:7.89%
controls:8.47%
6
85
82
795
6
25
82
855
—
—
—
—
6
63
70
681
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2.5e-01
1.8e-01
—
—
—
3.0e-01
3.8e-01
cases:18.18%
controls:14.77%
cases:9.09%
controls:7.73%
—
—
—
—
—
—
cases:9.52%
controls:7.24%
cases:25.00%
controls:18.55%
16
130
72
750
8
68
80
812
—
—
—
8
61
76
781
19
138
57
606
pravastatin; oral
C10AA03 [21601858]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
5
88
875
—
—
—
—
—
Examination of eyes and vision
Z01.0 [45566391]
9.5e-01
—
—
—
—
—
8.6e-01
cases:5.68%
controls:2.27%
—
—
—
—
—
—
—
—
—
—
cases:7.89%
controls:3.49%
5
20
83
860
—
—
—
—
—
6
26
70
718
Other complicated root filling
SGB30 [2001310390]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.25%
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
0
11
88
869
0
5
88
875
—
—
—
—
—
Salmonella sp identified in Stool by Organism specific culture
20955-1 [3004716]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
88
871
—
—
—
—
—
—
Limited function/disability (L)
L28 [2002000647]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
0
7
88
873
—
—
—
0
5
84
837
—
Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
0
8
84
834
—
Lumbar spine MRI examination with high intensity magnet
NA3BG [2001307034]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
88
870
—
—
—
—
—
—
macrogol; oral
A06AD15 [21600575]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
0
7
88
873
—
—
—
—
—
0
5
76
739
Immunohistochemistry procedure
117617002 [4035726]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.08%
0
6
88
874
—
—
—
—
—
0
8
76
736
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
1.1e+00
—
—
—
—
—
—
cases:12.50%
controls:4.55%
—
—
—
—
—
—
—
—
—
—
—
—
11
40
77
840
—
—
—
—
—
—
Depressive episode, unspecified
F32.9 [45571760]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
0
8
88
872
—
—
—
—
—
tiotropium bromide; inhalant
R03BB04 [21603296]
1.3e+00
—
—
—
—
—
—
cases:6.82%
controls:1.93%
—
—
—
—
—
—
—
—
—
—
—
—
6
17
82
863
—
—
—
—
—
—
Outlet vacuum delivery
MAE00 [2001306882]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
0
5
88
875
—
—
—
—
—
0
5
76
739
pH of Capillary blood
2745-8 [3009343]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
0
5
88
875
—
—
—
—
—
0
9
76
735
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
—
—
—
—
-1.0e+50
—
6.0e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
cases:14.47%
controls:8.47%
—
—
—
—
0
5
88
874
—
11
63
65
681
salbutamol; oral, parenteral
R03CC02 [21603312]
1.1e+00
—
—
—
—
—
—
cases:5.68%
controls:2.05%
—
—
—
—
—
—
—
—
—
—
—
—
5
18
83
862
—
—
—
—
—
—
Migraine with aura [classical migraine]
G43.1 [45562086]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
0
6
88
874
—
—
—
—
—
dydrogesterone; oral
G03DB01 [21602544]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
0
5
84
837
—
Pain localized to other parts of lower abdomen
R10.3 [45534426]
1.4e+00
—
—
—
—
—
7.2e-01
cases:9.09%
controls:2.50%
—
—
—
—
—
—
—
—
—
—
cases:9.21%
controls:4.70%
8
22
80
858
—
—
—
—
—
7
35
69
709
Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
11054-4 [3002109]
—
—
—
—
—
-1.0e+50
8.2e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
cases:7.89%
controls:3.63%
—
—
—
—
—
0
10
84
832
6
27
70
717
Excessive and frequent menstruation with irregular cycle
N92.1 [45539073]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
88
869
—
—
—
—
—
—
Venous insufficiency (chronic)(peripheral)
I87.2 [45552867]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.34%
—
—
—
—
—
—
0
10
76
734
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
88
873
—
—
—
—
—
—
Neck symptom/complaint
L01 [2002000626]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.31%
—
—
—
—
—
—
—
0
11
84
831
—
valsartan and diuretics
C09DA03 [21601836]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.91%
cases:0.00%
controls:0.57%
—
—
—
—
—
—
cases:0.00%
controls:0.95%
cases:0.00%
controls:1.08%
0
8
88
872
0
5
88
875
—
—
—
0
8
84
834
0
8
76
736
Headache
N01 [2002000720]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
0
5
84
837
—
encephalitis, tick borne, inactivated, whole virus
J07BA01 [21601331]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
88
864
—
—
—
—
—
—
Hypertension uncomplicated
K86 [2002000613]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
0
6
88
874
—
—
—
—
—
0
5
76
739
scopolamine
A04AD01 [21600499]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
88
872
—
—
—
—
—
—
venlafaxine; oral
N06AX16 [21604745]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
0
5
88
874
—
—
Balloon angioplasty and drug eluding stent
AN4 [2000200166]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
88
875
—
—
—
—
—
—
dextromethorphan, combinations; oral
N07XX59 [43534835]
1.1e+00
—
—
—
—
—
—
cases:5.68%
controls:2.05%
—
—
—
—
—
—
—
—
—
—
—
—
5
18
83
862
—
—
—
—
—
—
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
cases:5.95%
controls:1.31%
—
—
—
—
—
—
—
5
11
79
831
—
naproxcinod
M01AE18 [40254094]
2.8e-01
1.1e+00
—
—
—
4.1e-01
5.4e-02
cases:13.64%
controls:10.68%
cases:11.36%
controls:4.09%
—
—
—
—
—
—
cases:5.95%
controls:4.04%
cases:11.84%
controls:11.29%
12
94
76
786
10
36
78
844
—
—
—
5
34
79
808
9
84
67
660
Oral Surgery
19 [38004464]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
88
871
—
—
—
—
—
—
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
cases:5.95%
controls:1.90%
—
—
—
—
—
—
—
5
16
79
826
—
Malaise and fatigue
R53 [45553741]
—
—
—
—
—
—
5.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.58%
controls:4.03%
—
—
—
—
—
—
5
30
71
714
Other obstetric ultrasound examination
MA2XE [2001306838]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
88
875
—
—
—
—
—
—
liraglutide; parenteral
A10BJ02 [1123630]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
0
6
88
874
—
—
—
—
—
Optical coherence tomography (OCT) of ocular fundus
CK2X4 [2001301456]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
5
88
875
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
28
32
12.37
23.80
1.3
1.6
—
—
—
0
0
50
138
7.07
19.28
1.9
1.4
393.33
504.71
titre
0.43
18
34
24
42
7.48
14.08
2.4
1.6
14.06
3.69
iu/ml
—
5
7
29
71
5.60
12.00
2.9
1.9
12.07
10.25
g/l
0.93
29
65
72
372
6.15
11.55
15.4
6.3
57.33
57.93
%
0.19
72
357
72
373
6.12
11.48
15.7
6.4
0.74
0.71
%
0.19
72
348
72
374
6.09
11.42
15.8
6.3
2.69
2.81
%
0.21
72
353
72
375
6.06
11.35
15.8
6.3
8.87
8.36
%
0.95
72
354
72
378
5.98
11.15
15.9
6.4
28.11
27.67
%
0.14
72
363
23
59
4.92
8.81
1.8
1.7
1.12
1.17
g/l
0.14
23
54
73
429
5.12
8.73
5.5
3.9
0.00
0.00
estimate
-0.00
16
100
73
437
4.93
8.32
5.6
3.8
75.44
0.00
estimate
0.48
18
100
73
439
4.89
8.21
5.5
3.9
0.00
0.00
estimate
-0.00
16
95
54
268
3.63
8.05
14.3
5.3
—
—
—
0
0
63
347
3.87
7.94
3.8
3.4
6.44
6.08
ph
1.38
34
206
19
46
4.99
7.73
1.2
1.3
—
—
—
0
0
57
305
3.47
7.30
4.4
3.6
39.32
32.58
e6/l
0.10
39
208
42
191
3.29
6.97
1.6
1.3
11.09
36.92
iu/ml
1.77
13
54
43
212
3.01
6.03
7.7
5.7
—
—
—
0
0
48
258
2.89
5.65
3.2
3.0
62.83
37.68
e6/l
0.21
37
200
37
176
2.90
5.43
1.4
1.4
1.06
9.41
u/ml
1.89
16
69
8
6
14.47
5.18
1.4
1.0
—
—
—
0
0
25
99
3.13
5.02
2.4
1.5
—
—
—
0
0
45
247
2.68
4.91
3.4
3.8
7.40
7.40
ph
0.19
30
169
38
196
2.65
4.65
1.8
1.4
1.77
2.43
g/l
2.57
29
127
42
228
2.61
4.63
3.2
3.1
—
0.40
—
0
5
41
225
2.54
4.36
3.0
2.6
0.12
0.42
e6/l
1.83
34
164
9
13
7.57
4.28
1.2
1.2
—
—
—
0
0
24
105
2.77
3.97
2.2
2.4
101.74
81.11
ug/g
0.30
19
80
9
15
6.54
3.93
1.2
1.2
—
—
—
0
0
14
39
4.07
3.92
2.1
2.0
0.00
0.00
estimate
—
5
12
44
261
2.37
3.83
12.4
6.5
—
—
—
0
0
23
103
2.67
3.62
2.2
1.5
—
—
—
0
0
18
71
2.93
3.57
1.9
1.8
0.00
0.00
estimate
—
7
16
18
71
2.93
3.57
6.3
5.6
0.00
0.00
%
—
5
18
32
170
2.39
3.52
5.6
4.5
—
—
—
0
0
19
78
2.83
3.51
6.3
4.8
0.67
0.70
%
—
6
27
34
186
2.35
3.50
2.6
1.8
0.50
1.53
mg/l
1.84
29
154
18
72
2.89
3.48
6.6
4.9
0.00
0.24
%
—
5
21
21
92
2.68
3.43
5.7
7.6
105.95
103.61
mmol/l
1.65
21
92
13
44
3.29
3.29
1.3
1.1
—
—
—
0
0
16
64
2.83
3.08
1.5
1.5
—
—
—
0
0
17
71
2.73
3.02
6.7
5.0
0.40
0.53
%
—
5
20
23
112
2.43
3.02
1.6
2.2
—
—
—
0
0
8
17
5.06
2.99
1.3
1.4
—
—
—
0
0
37
222
2.15
2.97
4.3
2.4
—
—
—
0
0
32
182
2.19
2.93
2.8
2.6
8.96
5.11
e6/l
0.40
32
164
22
109
2.36
2.76
1.1
1.6
—
—
—
0
0
12
41
3.23
2.75
7.8
11.0
23.65
24.45
mmol/l
0.49
12
41
6
10
6.34
2.74
1.2
1.2
—
—
—
0
0
50
345
2.04
2.70
5.6
3.7
0.00
0.00
estimate
-0.00
12
86
21
104
2.34
2.63
2.2
3.9
4.28
9.39
e9/l
0.79
21
95
39
248
2.03
2.62
6.9
3.9
0.00
0.00
estimate
-0.00
17
94
10
32
3.39
2.53
1.1
1.3
—
95.00
—
0
6
14
58
2.68
2.52
7.5
8.8
—
—
—
0
0
5
8
6.54
2.40
1.2
1.3
—
—
—
0
0
5
8
6.54
2.40
1.2
1.3
—
—
—
0
0
5
8
6.54
2.40
1.2
1.3
—
—
—
0
0
5
8
6.54
2.40
1.2
1.3
—
—
—
0
0
12
48
2.74
2.30
6.8
8.3
24.00
24.86
mmol/l
0.37
12
48
25
141
2.08
2.28
1.5
1.6
—
—
—
0
0
15
70
2.38
2.13
6.5
9.4
7.42
7.41
ph
—
7
42
34
219
1.90
2.12
1.5
1.3
3.53
1.51
u/ml
0.27
12
61
10
38
2.84
2.08
1.8
2.4
0.58
0.66
%
—
10
38
6
15
4.21
2.07
1.5
1.2
—
—
—
0
0
39
266
1.84
2.02
5.5
3.2
0.00
0.01
estimate
0.49
13
83
6
16
3.94
1.97
1.0
1.3
—
—
—
0
0
13
59
2.41
1.95
7.5
8.1
0.95
1.23
mmol/l
0.66
13
59
14
66
2.33
1.94
1.7
3.2
0.06
0.10
e6/l
0.28
14
61
21
118
2.02
1.91
1.1
1.2
—
—
—
0
0
8
28
3.04
1.91
1.0
1.2
1.59
1.69
g/l
—
8
28
8
29
2.93
1.84
1.0
1.2
0.79
0.81
g/l
—
8
29
20
113
2.00
1.79
2.6
2.2
21.79
24.05
%
0.29
20
105
16
84
2.11
1.73
2.2
1.3
—
—
—
0
0
10
40
2.69
1.73
1.8
2.5
1.00
1.32
%
—
10
40
5
14
3.72
1.64
1.0
1.4
—
—
—
0
0
5
14
3.72
1.64
1.4
1.7
47.40
50.99
%
—
5
14
5
14
3.72
1.64
1.4
1.8
48.20
52.45
%
—
5
14
24
150
1.83
1.60
3.3
2.6
589.50
538.93
mosm/kgh2o
0.38
24
128
22
134
1.86
1.58
3.2
2.2
11.65
14.16
umol/l
0.85
22
122
45
338
1.68
1.57
2.6
1.9
—
—
—
0
0
13
66
2.14
1.52
1.2
1.2
42.03
141.83
u/ml
—
7
21
35
248
1.68
1.51
2.1
2.3
—
—
—
0
0
13
67
2.10
1.47
3.1
2.6
7.41
7.39
ph
—
7
39
62
512
1.71
1.47
6.4
4.1
—
43.88
—
0
8
76
669
2.00
1.41
36.1
17.8
13.99
13.56
%
1.97
76
662
49
384
1.62
1.40
4.8
3.2
108.49
103.27
ug/l
0.08
49
364
42
319
1.61
1.35
2.2
2.0
99.89
95.24
pmol/l
0.23
26
169
44
339
1.60
1.33
24.4
10.3
1.22
1.17
inr
0.24
35
274
8
35
2.41
1.31
2.8
2.1
25.10
24.59
mmol/l
—
8
35
11
56
2.10
1.28
3.0
2.6
78.84
80.85
e9/l
—
5
38
24
161
1.67
1.24
1.9
1.9
—
—
—
0
0
27
188
1.63
1.21
3.4
3.9
1.02
1.02
kg/l
0.32
17
118
21
137
1.70
1.20
4.5
3.2
169.91
357.20
ng/l
0.34
11
95
45
357
1.53
1.15
2.2
2.8
—
—
estimate
—
0
0
14
84
1.79
1.05
1.4
1.8
—
—
—
0
0
8
43
1.94
0.90
1.1
1.2
—
—
—
0
0
8
46
1.81
0.85
1.8
1.3
—
—
—
0
0
54
464
1.42
0.82
4.4
4.8
6.13
6.52
mmol/l
1.14
54
436
36
290
1.41
0.78
5.0
3.7
15.60
42.58
ng/l
1.24
23
190
5
24
2.15
0.76
1.6
1.3
7.14
8.14
u/l
—
5
18
5
30
1.71
0.62
1.6
1.8
—
—
—
0
0
8
52
1.59
0.61
1.1
1.1
—
—
—
0
0
20
253
0.73
0.55
3.8
4.0
2.44
8.88
mg/mmol
1.69
14
155
13
96
1.42
0.44
3.5
2.2
324.77
360.16
nmol/l
0.35
13
90
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
13
98
1.38
0.40
3.1
4.8
0.99
1.02
mmol/l
0.13
13
91
21
248
0.80
0.34
2.9
3.4
11.49
53.32
mg/l
2.20
15
161
10
76
1.36
0.29
1.1
1.2
—
—
—
0
0
32
356
0.84
0.28
2.6
3.2
—
—
—
0
0
20
229
0.84
0.23
1.2
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
91.59
—
0
11
0
10
0.00
0.21
0.0
2.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
14
163
0.83
0.19
1.9
1.7
465.57
469.12
pmol/l
0.02
14
141
6
78
0.75
0.16
14.0
2.8
—
—
—
0
0
11
93
1.21
0.15
1.7
1.5
—
—
—
0
0
17
185
0.90
0.09
7.0
5.9
1.53
1.86
ug/l
0.31
17
169
28
264
1.09
0.09
4.5
3.3
—
—
—
0
0
6
71
0.83
0.08
1.0
1.3
—
—
—
0
0
80
788
1.17
0.07
5.2
6.0
2.81
2.77
mmol/l
0.17
80
734
11
99
1.13
0.07
1.3
1.2
—
—
—
0
0
14
129
1.10
0.06
3.4
3.0
0.87
0.83
mmol/l
1.20
14
124
78
778
1.02
0.00
4.5
5.2
1.50
1.50
mmol/l
0.00
78
721
63
635
0.97
0.00
6.8
4.9
14.67
14.59
pmol/l
0.08
63
597
11
109
1.01
0.00
2.3
1.2
—
—
—
0
0
6
59
1.02
-0.00
1.2
1.9
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
58.57
—
0
7
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
17.3
—
870.67
—
0
9
0
5
0.00
-0.00
0.0
1.4
—
5.24
—
0
5
0
6
0.00
-0.00
0.0
3.0
—
5.55
—
0
6
0
5
0.00
-0.00
0.0
4.2
—
0.89
—
0
5
5
56
0.89
-0.00
1.2
1.2
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint M13_RELAPSPOLYCHONDR and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have M13_RELAPSPOLYCHONDR.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: M13_RELAPSPOLYCHONDR – Relapsing polychondritis

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data